Prospects for the Use of ATR Inhibitors to Treat Cancer

ATR is an apical kinase in one of the DNA-damage induced checkpoint pathways. Despite the development of inhibitors of kinases structurally related to ATR, as well as inhibitors of the ATR substrate Chk1, no ATR inhibitors have yet been developed. Here we review the effects of ATR downregulation in...

Descripción completa

Detalles Bibliográficos
Autores principales: Wagner, Jill M., Kaufmann, Scott H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033983/
https://www.ncbi.nlm.nih.gov/pubmed/27713304
http://dx.doi.org/10.3390/ph3051311
Descripción
Sumario:ATR is an apical kinase in one of the DNA-damage induced checkpoint pathways. Despite the development of inhibitors of kinases structurally related to ATR, as well as inhibitors of the ATR substrate Chk1, no ATR inhibitors have yet been developed. Here we review the effects of ATR downregulation in cancer cells and discuss the potential for development of ATR inhibitors for clinical use.

Ejemplares similares